These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31835432)

  • 21. Hybridization capture-based next generation sequencing reliably detects FLT3 mutations and classifies FLT3-internal tandem duplication allelic ratio in acute myeloid leukemia: a comparative study to standard fragment analysis.
    He R; Devine DJ; Tu ZJ; Mai M; Chen D; Nguyen PL; Oliveira JL; Hoyer JD; Reichard KK; Ollila PL; Al-Kali A; Tefferi A; Begna KH; Patnaik MM; Alkhateeb H; Viswanatha DS
    Mod Pathol; 2020 Mar; 33(3):334-343. PubMed ID: 31471587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A clinicopathological experience in acute myeloid leukemia: Effects of clinical data and status of FLT3, CEBPA and NPM1 on prognosis.
    Yener E; Ozcan K; Öngören Ş; Salihoğlu A; Demiröz AS; Akı H
    Indian J Pathol Microbiol; 2022; 65(3):642-648. PubMed ID: 35900493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
    Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
    Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
    Mendoza H; Podoltsev NA; Siddon AJ
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiplex high-throughput gene mutation analysis in acute myeloid leukemia.
    Dunlap J; Beadling C; Warrick A; Neff T; Fleming WH; Loriaux M; Heinrich MC; Kovacsovics T; Kelemen K; Leeborg N; Gatter K; Braziel RM; Press R; Corless CL; Fan G
    Hum Pathol; 2012 Dec; 43(12):2167-76. PubMed ID: 22658276
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients.
    Mechaal A; Menif S; Abbes S; Safra I
    Adv Med Sci; 2019 Sep; 64(2):395-401. PubMed ID: 31331874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
    Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
    BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ
    Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prognostic significance of minimal residual disease before post-remission therapy in younger adult acute myeloid leukemia patients with intermediate risk and negative of FLT3-ITD, NPM1 and biallelic CEBPA mutations].
    Zhang Y; Zhang YM; Zhang YS; Tang GS; Zhang WP; Yang JM; Wang JM; Hu XX
    Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):597-601. PubMed ID: 32397025
    [No Abstract]   [Full Text] [Related]  

  • 31. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia.
    Damm F; Heuser M; Morgan M; Yun H; Grosshennig A; Göhring G; Schlegelberger B; Döhner K; Ottmann O; Lübbert M; Heit W; Kanz L; Schlimok G; Raghavachar A; Fiedler W; Kirchner H; Döhner H; Heil G; Ganser A; Krauter J
    J Clin Oncol; 2010 Feb; 28(4):578-85. PubMed ID: 20038731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
    Gaidzik VI; Bullinger L; Schlenk RF; Zimmermann AS; Röck J; Paschka P; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Späth D; Kündgen A; Schmidt-Wolf IG; Götze K; Nachbaur D; Pfreundschuh M; Horst HA; Döhner H; Döhner K
    J Clin Oncol; 2011 Apr; 29(10):1364-72. PubMed ID: 21343560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of FLT3 and NPM1 Mutations in Patients with Acute Myeloid Leukaemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2019 Jun; 20(6):1749-1755. PubMed ID: 31244296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NPM1, FLT3-ITD, CEBPA, and c-kit mutations in 312 Chinese patients with de novo acute myeloid leukemia.
    Su L; Gao SJ; Li W; Tan YH; Cui JW; Hu RP
    Hematology; 2014 Sep; 19(6):324-8. PubMed ID: 24164801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutational landscape of AML with normal cytogenetics: biological and clinical implications.
    Martelli MP; Sportoletti P; Tiacci E; Martelli MF; Falini B
    Blood Rev; 2013 Jan; 27(1):13-22. PubMed ID: 23261068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.
    Patel KP; Ravandi F; Ma D; Paladugu A; Barkoh BA; Medeiros LJ; Luthra R
    Am J Clin Pathol; 2011 Jan; 135(1):35-45. PubMed ID: 21173122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia: implications for clinical practice.
    Lin PH; Li HY; Fan SC; Yuan TH; Chen M; Hsu YH; Yang YH; Li LY; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Lin CH; Lien MY; Chen TT; Ni YH; Chiu CF
    Cancer Med; 2017 Feb; 6(2):349-360. PubMed ID: 28070990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia.
    Kuzmanovic M; Tosic N; Colovic N; Karan-Djurasevic T; Spasovski V; Radmilovic M; Nikcevic G; Suvajdzic-Vukovic N; Tomin D; Vidovic A; Virijevic M; Pavlovic S; Colovic M
    Acta Haematol; 2012; 128(4):203-12. PubMed ID: 22906848
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML.
    Ahn JS; Kim HJ; Kim YK; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
    Ann Hematol; 2016 Mar; 95(4):625-35. PubMed ID: 26692090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Correlation of adult AML Npm1 mutations with prognosis and its relationship with gene mutation of FLT3 and CEBPA].
    Bao LY; Wang JS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):19-24. PubMed ID: 20137111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.